top of page

The Science: Complimentary Treatments

StiRx currently has a primary focus on a Gonococcal vaccine (STX-430/428) and gonococcal mAb (STX 426), with a chlamydia vaccine (STX-288) and other STI treatments in the exploratory phase of research.


Treatment as adjunctive therapy for antibiotic resistant N. gonorrhoeae for acute infections and high risk patients, or for topical application as preventative


Disease prevention in

all at-risk patient populations

bottom of page